Pfizer Outlines Post-2028 Growth Strategy Focused on Obesity Drugs
Pfizer outlined its strategy for returning to stronger growth after 2028, driven by obesity drugs in development and a patent extension for Vyndamax. The company also reported first-quarter results that beat Wall Street expectations due to strong demand for Eliquis and recent acquisitions.
Topics: cancer drugs obesity drugs patent extension pipeline strategy revenue growth